Effect of galcanezumab in women with episodic migraine meeting criteria for menstrually related migraine: A post hoc analysis of EVOLVE‐1 and EVOLVE‐2

Background We evaluated galcanezumab for migraine prevention in patients who met International Classification of Headache Disorders, 3rd edition criteria for menstrually related migraine (MRM). Methods Patients were identified post hoc from three double‐blind, randomized, phase 3 clinical trials in...

Full description

Saved in:
Bibliographic Details
Published inHeadache Vol. 64; no. 2; pp. 179 - 187
Main Authors MacGregor, E. Anne, Okonkwo, Rose, Detke, Holland C., Polavieja, Pepa, Fernandes, Maria S., Pavlovic, Jelena M.
Format Journal Article
LanguageEnglish
Published United States Wiley Subscription Services, Inc 01.02.2024
Subjects
Antibodies, Monoclonal, Humanized
calcitonin gene–related peptide antibody
Clinical trials
Criteria
Diaries
Double-Blind Method
Female
galcanezumab
Headache
Headaches
Humans
menstrual migraine
menstrually related migraine
Migraine
Migraine Disorders - drug therapy
Migraine Disorders - prevention & control
migraine prevention
Monoclonal antibodies
Patients
Placebos
Prevention
Prospective Studies
Quality of Life
Response rates
Standard error
Treatment Outcome
calcitonin gene-related peptide antibody
migraine prevention
galcanezumab
menstrually related migraine
menstrual migraine
Online AccessGet full text

Cover

Abstract Background We evaluated galcanezumab for migraine prevention in patients who met International Classification of Headache Disorders, 3rd edition criteria for menstrually related migraine (MRM). Methods Patients were identified post hoc from three double‐blind, randomized, phase 3 clinical trials in patients with episodic migraine. Patients completed a 1‐month prospective baseline period and up to 6 months (EVOLVE‐1 and ‐2, studies pooled) of double‐blind treatment with galcanezumab (120 mg/month) or placebo. Menses and headache information were recorded by electronic daily diary. Patients with a migraine attack starting during the 5‐day perimenstrual interval (first day of bleeding ± 2 days) for ≥2 of their first three diary‐recorded menstrual cycles were categorized as having MRM. The primary efficacy measure was mean change in monthly migraine headache days from baseline, averaged over Months 4 through 6. Response rates, change in monthly perimenstrual migraine headache days, monthly non‐perimenstrual migraine headache days, and quality of life were also assessed. Results Post hoc MRM analysis criteria were met by 462/1133 women (41%). Mean (standard deviation) baseline monthly migraine headache days were 9.7 (±3.1; n = 146) for galcanezumab‐treated patients and 9.6 (±2.8; n = 316) for placebo‐treated patients. The mean change (standard error [SE]) in migraine headache days over Months 4 through 6 was −5.1 days (±0.39) for galcanezumab versus −3.2 (±0.35) for placebo (p < 0.001). The mean change (SE) in perimenstrual migraine headache days over Months 4 through 6 was −0.75 days (±0.08) for galcanezumab versus −0.49 (±0.07) for placebo (p = 0.004). For migraine headache days outside the perimenstrual period, the mean change in migraine headache days was −4.6 (±0.38) for galcanezumab and −2.8 (±0.33) for placebo (p < 0.001). Improvements in response rates and the Migraine‐Specific Quality of Life Questionnaire were also observed over Months 4 through 6. Conclusion Galcanezumab was effective for migraine prevention in women with MRM.
AbstractList We evaluated galcanezumab for migraine prevention in patients who met International Classification of Headache Disorders, 3rd edition criteria for menstrually related migraine (MRM).BACKGROUNDWe evaluated galcanezumab for migraine prevention in patients who met International Classification of Headache Disorders, 3rd edition criteria for menstrually related migraine (MRM).Patients were identified post hoc from three double-blind, randomized, phase 3 clinical trials in patients with episodic migraine. Patients completed a 1-month prospective baseline period and up to 6 months (EVOLVE-1 and -2, studies pooled) of double-blind treatment with galcanezumab (120 mg/month) or placebo. Menses and headache information were recorded by electronic daily diary. Patients with a migraine attack starting during the 5-day perimenstrual interval (first day of bleeding ± 2 days) for ≥2 of their first three diary-recorded menstrual cycles were categorized as having MRM. The primary efficacy measure was mean change in monthly migraine headache days from baseline, averaged over Months 4 through 6. Response rates, change in monthly perimenstrual migraine headache days, monthly non-perimenstrual migraine headache days, and quality of life were also assessed.METHODSPatients were identified post hoc from three double-blind, randomized, phase 3 clinical trials in patients with episodic migraine. Patients completed a 1-month prospective baseline period and up to 6 months (EVOLVE-1 and -2, studies pooled) of double-blind treatment with galcanezumab (120 mg/month) or placebo. Menses and headache information were recorded by electronic daily diary. Patients with a migraine attack starting during the 5-day perimenstrual interval (first day of bleeding ± 2 days) for ≥2 of their first three diary-recorded menstrual cycles were categorized as having MRM. The primary efficacy measure was mean change in monthly migraine headache days from baseline, averaged over Months 4 through 6. Response rates, change in monthly perimenstrual migraine headache days, monthly non-perimenstrual migraine headache days, and quality of life were also assessed.Post hoc MRM analysis criteria were met by 462/1133 women (41%). Mean (standard deviation) baseline monthly migraine headache days were 9.7 (±3.1; n = 146) for galcanezumab-treated patients and 9.6 (±2.8; n = 316) for placebo-treated patients. The mean change (standard error [SE]) in migraine headache days over Months 4 through 6 was -5.1 days (±0.39) for galcanezumab versus -3.2 (±0.35) for placebo (p < 0.001). The mean change (SE) in perimenstrual migraine headache days over Months 4 through 6 was -0.75 days (±0.08) for galcanezumab versus -0.49 (±0.07) for placebo (p = 0.004). For migraine headache days outside the perimenstrual period, the mean change in migraine headache days was -4.6 (±0.38) for galcanezumab and -2.8 (±0.33) for placebo (p < 0.001). Improvements in response rates and the Migraine-Specific Quality of Life Questionnaire were also observed over Months 4 through 6.RESULTSPost hoc MRM analysis criteria were met by 462/1133 women (41%). Mean (standard deviation) baseline monthly migraine headache days were 9.7 (±3.1; n = 146) for galcanezumab-treated patients and 9.6 (±2.8; n = 316) for placebo-treated patients. The mean change (standard error [SE]) in migraine headache days over Months 4 through 6 was -5.1 days (±0.39) for galcanezumab versus -3.2 (±0.35) for placebo (p < 0.001). The mean change (SE) in perimenstrual migraine headache days over Months 4 through 6 was -0.75 days (±0.08) for galcanezumab versus -0.49 (±0.07) for placebo (p = 0.004). For migraine headache days outside the perimenstrual period, the mean change in migraine headache days was -4.6 (±0.38) for galcanezumab and -2.8 (±0.33) for placebo (p < 0.001). Improvements in response rates and the Migraine-Specific Quality of Life Questionnaire were also observed over Months 4 through 6.Galcanezumab was effective for migraine prevention in women with MRM.CONCLUSIONGalcanezumab was effective for migraine prevention in women with MRM.
Background We evaluated galcanezumab for migraine prevention in patients who met International Classification of Headache Disorders, 3rd edition criteria for menstrually related migraine (MRM). Methods Patients were identified post hoc from three double‐blind, randomized, phase 3 clinical trials in patients with episodic migraine. Patients completed a 1‐month prospective baseline period and up to 6 months (EVOLVE‐1 and ‐2, studies pooled) of double‐blind treatment with galcanezumab (120 mg/month) or placebo. Menses and headache information were recorded by electronic daily diary. Patients with a migraine attack starting during the 5‐day perimenstrual interval (first day of bleeding ± 2 days) for ≥2 of their first three diary‐recorded menstrual cycles were categorized as having MRM. The primary efficacy measure was mean change in monthly migraine headache days from baseline, averaged over Months 4 through 6. Response rates, change in monthly perimenstrual migraine headache days, monthly non‐perimenstrual migraine headache days, and quality of life were also assessed. Results Post hoc MRM analysis criteria were met by 462/1133 women (41%). Mean (standard deviation) baseline monthly migraine headache days were 9.7 (±3.1; n = 146) for galcanezumab‐treated patients and 9.6 (±2.8; n = 316) for placebo‐treated patients. The mean change (standard error [SE]) in migraine headache days over Months 4 through 6 was −5.1 days (±0.39) for galcanezumab versus −3.2 (±0.35) for placebo (p < 0.001). The mean change (SE) in perimenstrual migraine headache days over Months 4 through 6 was −0.75 days (±0.08) for galcanezumab versus −0.49 (±0.07) for placebo (p = 0.004). For migraine headache days outside the perimenstrual period, the mean change in migraine headache days was −4.6 (±0.38) for galcanezumab and −2.8 (±0.33) for placebo (p < 0.001). Improvements in response rates and the Migraine‐Specific Quality of Life Questionnaire were also observed over Months 4 through 6. Conclusion Galcanezumab was effective for migraine prevention in women with MRM.
BackgroundWe evaluated galcanezumab for migraine prevention in patients who met International Classification of Headache Disorders, 3rd edition criteria for menstrually related migraine (MRM).MethodsPatients were identified post hoc from three double‐blind, randomized, phase 3 clinical trials in patients with episodic migraine. Patients completed a 1‐month prospective baseline period and up to 6 months (EVOLVE‐1 and ‐2, studies pooled) of double‐blind treatment with galcanezumab (120 mg/month) or placebo. Menses and headache information were recorded by electronic daily diary. Patients with a migraine attack starting during the 5‐day perimenstrual interval (first day of bleeding ± 2 days) for ≥2 of their first three diary‐recorded menstrual cycles were categorized as having MRM. The primary efficacy measure was mean change in monthly migraine headache days from baseline, averaged over Months 4 through 6. Response rates, change in monthly perimenstrual migraine headache days, monthly non‐perimenstrual migraine headache days, and quality of life were also assessed.ResultsPost hoc MRM analysis criteria were met by 462/1133 women (41%). Mean (standard deviation) baseline monthly migraine headache days were 9.7 (±3.1; n = 146) for galcanezumab‐treated patients and 9.6 (±2.8; n = 316) for placebo‐treated patients. The mean change (standard error [SE]) in migraine headache days over Months 4 through 6 was −5.1 days (±0.39) for galcanezumab versus −3.2 (±0.35) for placebo (p < 0.001). The mean change (SE) in perimenstrual migraine headache days over Months 4 through 6 was −0.75 days (±0.08) for galcanezumab versus −0.49 (±0.07) for placebo (p = 0.004). For migraine headache days outside the perimenstrual period, the mean change in migraine headache days was −4.6 (±0.38) for galcanezumab and −2.8 (±0.33) for placebo (p < 0.001). Improvements in response rates and the Migraine‐Specific Quality of Life Questionnaire were also observed over Months 4 through 6.ConclusionGalcanezumab was effective for migraine prevention in women with MRM.
We evaluated galcanezumab for migraine prevention in patients who met International Classification of Headache Disorders, 3rd edition criteria for menstrually related migraine (MRM). Patients were identified post hoc from three double-blind, randomized, phase 3 clinical trials in patients with episodic migraine. Patients completed a 1-month prospective baseline period and up to 6 months (EVOLVE-1 and -2, studies pooled) of double-blind treatment with galcanezumab (120 mg/month) or placebo. Menses and headache information were recorded by electronic daily diary. Patients with a migraine attack starting during the 5-day perimenstrual interval (first day of bleeding ± 2 days) for ≥2 of their first three diary-recorded menstrual cycles were categorized as having MRM. The primary efficacy measure was mean change in monthly migraine headache days from baseline, averaged over Months 4 through 6. Response rates, change in monthly perimenstrual migraine headache days, monthly non-perimenstrual migraine headache days, and quality of life were also assessed. Post hoc MRM analysis criteria were met by 462/1133 women (41%). Mean (standard deviation) baseline monthly migraine headache days were 9.7 (±3.1; n = 146) for galcanezumab-treated patients and 9.6 (±2.8; n = 316) for placebo-treated patients. The mean change (standard error [SE]) in migraine headache days over Months 4 through 6 was -5.1 days (±0.39) for galcanezumab versus -3.2 (±0.35) for placebo (p < 0.001). The mean change (SE) in perimenstrual migraine headache days over Months 4 through 6 was -0.75 days (±0.08) for galcanezumab versus -0.49 (±0.07) for placebo (p = 0.004). For migraine headache days outside the perimenstrual period, the mean change in migraine headache days was -4.6 (±0.38) for galcanezumab and -2.8 (±0.33) for placebo (p < 0.001). Improvements in response rates and the Migraine-Specific Quality of Life Questionnaire were also observed over Months 4 through 6. Galcanezumab was effective for migraine prevention in women with MRM.
Author Fernandes, Maria S.
Okonkwo, Rose
Pavlovic, Jelena M.
MacGregor, E. Anne
Detke, Holland C.
Polavieja, Pepa
Author_xml – sequence: 1
  givenname: E. Anne
  orcidid: 0000-0002-4116-9828
  surname: MacGregor
  fullname: MacGregor, E. Anne
  organization: Centre for Reproductive Medicine, St Bartholomew's Hospital
– sequence: 2
  givenname: Rose
  surname: Okonkwo
  fullname: Okonkwo, Rose
  email: okonkwo_rose@lilly.com
  organization: Eli Lilly and Company
– sequence: 3
  givenname: Holland C.
  orcidid: 0000-0002-1316-6064
  surname: Detke
  fullname: Detke, Holland C.
  organization: Eli Lilly and Company
– sequence: 4
  givenname: Pepa
  surname: Polavieja
  fullname: Polavieja, Pepa
  organization: Eli Lilly and Company
– sequence: 5
  givenname: Maria S.
  surname: Fernandes
  fullname: Fernandes, Maria S.
  organization: Eli Lilly and Company
– sequence: 6
  givenname: Jelena M.
  surname: Pavlovic
  fullname: Pavlovic, Jelena M.
  organization: Albert Einstein College of Medicine, Montefiore Headache Center
BackLink https://www.ncbi.nlm.nih.gov/pubmed/38017629$$D View this record in MEDLINE/PubMed
BookMark eNp9kUFvFCEUx4mpsdvqxQ9gSLyYJlOBgZnB26aO1mSTXrRXwjCwS8PACkya9eRH8OzH6yeRdVtNGiMHyHvv93_k_d8JOPLBawBeYnSOy3m70XI8x7Rh5AlYYEaaijYYHYEFQritupZ2x-AkpRuEEG148wwc112pNIQvwM_eGK0yDAaupVPS62_zJAdoPbwNky63zRuotzaF0So42XWU1ms4aZ2tX0MVbdbRSmhCLEmfcpylczsYtZNZj38U7-ASbkPKcBMUlF66XbJp_21_fbW67u--_8AlPf4NyXPw1EiX9Iv79xR8-dB_vrisVlcfP10sV5WqeU2qgRnSSS5Rw9rOlOlxVxtqqOIDknxQA0NtR0tl4LiVnJJhZIowNrS8blta16fgzaHvNoavs05ZTDYp7VwxI8xJkI7vu1LKCvr6EXoT5liGKRQnLWIcd6hQr-6peZj0KLbRTjLuxIPrBUAHQMWQUtRGKJtltsHn4pUTGIn9YsV-seL3Yovk7JHkoes_YXyAb63Tu_-Q4rJfvj9ofgHoGrPp
CitedBy_id crossref_primary_10_1111_head_14783
crossref_primary_10_48208_HeadacheMed_2024_44
Cites_doi 10.1212/WNL.0b013e3182535d20
10.1177/0333102413507637
10.1001/jamaneurol.2018.1212
10.1111/head.12978
10.1212/WNL.0000000000012723
10.1186/s10194-020-01167-6
10.1177/0333102417738202
10.1038/s41467-020-15436-0
10.1093/brain/aww015
10.1007/s11136-007-9217-1
10.1177/03331024221099031
10.1212/WNL.0000000000012741
10.1111/j.1468-2982.2004.00741.x
10.1177/0333102418779543
10.1177/1756285609335537
10.1016/j.maturitas.2020.07.005
10.1186/s10194-015-0503-y
10.1016/S1474-4422(20)30482-8
10.1177/0333102413485658
10.1038/s41582-018-0003-1
10.1212/WNL.0000000000207114
10.1038/s41582-021-00544-2
ContentType Journal Article
Copyright 2023 Eli Lilly and Company and The Authors. published by Wiley Periodicals LLC on behalf of American Headache Society.
2023 Eli Lilly and Company and The Authors. Headache: The Journal of Head and Face Pain published by Wiley Periodicals LLC on behalf of American Headache Society.
2023. This article is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: 2023 Eli Lilly and Company and The Authors. published by Wiley Periodicals LLC on behalf of American Headache Society.
– notice: 2023 Eli Lilly and Company and The Authors. Headache: The Journal of Head and Face Pain published by Wiley Periodicals LLC on behalf of American Headache Society.
– notice: 2023. This article is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID 24P
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7TK
7U7
C1K
K9.
7X8
DOI 10.1111/head.14652
DatabaseName Wiley Online Library Open Access
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Neurosciences Abstracts
Toxicology Abstracts
Environmental Sciences and Pollution Management
ProQuest Health & Medical Complete (Alumni)
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest Health & Medical Complete (Alumni)
Toxicology Abstracts
Neurosciences Abstracts
Environmental Sciences and Pollution Management
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic

ProQuest Health & Medical Complete (Alumni)
MEDLINE
Database_xml – sequence: 1
  dbid: 24P
  name: Wiley Online Library Open Access
  url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html
  sourceTypes: Publisher
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1526-4610
EndPage 187
ExternalDocumentID 38017629
10_1111_head_14652
HEAD14652
Genre researchArticle
Randomized Controlled Trial
Journal Article
GrantInformation_xml – fundername: Eli Lilly and Company
GroupedDBID ---
.3N
.GA
.GJ
.Y3
05W
0R~
10A
1OB
1OC
24P
29I
31~
33P
36B
3SF
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5HH
5LA
5RE
5VS
66C
6PF
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHQN
AAIPD
AAMMB
AAMNL
AANHP
AANLZ
AAONW
AAQQT
AASGY
AAWTL
AAXRX
AAYCA
AAZKR
ABCQN
ABCUV
ABEML
ABIVO
ABJNI
ABPVW
ABQWH
ABXGK
ACAHQ
ACBWZ
ACCZN
ACGFS
ACGOF
ACMXC
ACPOU
ACPRK
ACRPL
ACSCC
ACXBN
ACXQS
ACYXJ
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADNMO
ADOZA
ADXAS
ADZMN
AEFGJ
AEIGN
AEIMD
AENEX
AEUYR
AEYWJ
AFBPY
AFEBI
AFFNX
AFFPM
AFGKR
AFRAH
AFWVQ
AFZJQ
AGHNM
AGQPQ
AGXDD
AGYGG
AHBTC
AHMBA
AI.
AIACR
AIDQK
AIDYY
AITYG
AIURR
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMBMR
AMYDB
ASPBG
ATUGU
AVWKF
AZBYB
AZFZN
AZVAB
BAFTC
BDRZF
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BY8
C45
CAG
COF
D-6
D-7
D-E
D-F
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
EBS
ECV
EJD
EMOBN
EX3
F00
F01
F04
F5P
FEDTE
FUBAC
FYBCS
G-S
G.N
GODZA
H.X
HF~
HGLYW
HVGLF
HZI
HZ~
IHE
IX1
J0M
K48
KBYEO
L7B
LATKE
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
O66
O9-
OIG
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
PALCI
PQQKQ
Q.N
Q11
QB0
R.K
RIWAO
RJQFR
ROL
RX1
SAMSI
SUPJJ
TEORI
UB1
VH1
W8V
W99
WBKPD
WHWMO
WIH
WIJ
WIK
WOHZO
WOW
WQ9
WQJ
WVDHM
WXI
WXSBR
XG1
YFH
YUY
ZGI
ZXP
ZZTAW
~IA
~WT
AAHHS
AAYXX
ACCFJ
ADZOD
AEEZP
AEQDE
AIWBW
AJBDE
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7TK
7U7
C1K
K9.
7X8
ID FETCH-LOGICAL-c3932-b5f28a9a06578f526183f4f4c9b0a9bcb507848f5b917a942bd5c255b79377433
IEDL.DBID DR2
ISSN 0017-8748
1526-4610
IngestDate Fri Jul 11 11:46:47 EDT 2025
Sun Jul 13 04:04:02 EDT 2025
Mon Jul 21 05:58:31 EDT 2025
Tue Jul 01 04:22:07 EDT 2025
Thu Apr 24 22:51:38 EDT 2025
Sun Jul 06 04:45:35 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 2
Keywords calcitonin gene-related peptide antibody
migraine prevention
galcanezumab
menstrually related migraine
menstrual migraine
Language English
License Attribution-NonCommercial-NoDerivs
2023 Eli Lilly and Company and The Authors. Headache: The Journal of Head and Face Pain published by Wiley Periodicals LLC on behalf of American Headache Society.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c3932-b5f28a9a06578f526183f4f4c9b0a9bcb507848f5b917a942bd5c255b79377433
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Article-2
ObjectType-Undefined-1
ObjectType-Feature-3
content type line 23
ORCID 0000-0002-4116-9828
0000-0002-1316-6064
OpenAccessLink https://proxy.k.utb.cz/login?url=https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fhead.14652
PMID 38017629
PQID 2927059180
PQPubID 24968
PageCount 9
ParticipantIDs proquest_miscellaneous_2895261445
proquest_journals_2927059180
pubmed_primary_38017629
crossref_citationtrail_10_1111_head_14652
crossref_primary_10_1111_head_14652
wiley_primary_10_1111_head_14652_HEAD14652
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate February 2024
2024-02-00
20240201
PublicationDateYYYYMMDD 2024-02-01
PublicationDate_xml – month: 02
  year: 2024
  text: February 2024
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: Mt. Royal
PublicationTitle Headache
PublicationTitleAlternate Headache
PublicationYear 2024
Publisher Wiley Subscription Services, Inc
Publisher_xml – name: Wiley Subscription Services, Inc
References 2021; 97
2021; 20
2015; 16
2013; 33
2020; 142
2021; 17
2017; 57
2023; 100
2004; 24
2016; 139
2022; 42
2020; 11
2020; 21
2009; 2
2012; 78
2018; 75
2014; 34
2018; 38
2018; 14
2007; 16
e_1_2_11_10_1
e_1_2_11_21_1
e_1_2_11_20_1
e_1_2_11_14_1
e_1_2_11_13_1
e_1_2_11_9_1
e_1_2_11_12_1
e_1_2_11_23_1
e_1_2_11_8_1
e_1_2_11_11_1
e_1_2_11_22_1
e_1_2_11_7_1
e_1_2_11_18_1
e_1_2_11_6_1
e_1_2_11_17_1
e_1_2_11_5_1
e_1_2_11_16_1
e_1_2_11_4_1
e_1_2_11_15_1
e_1_2_11_3_1
e_1_2_11_2_1
e_1_2_11_19_1
References_xml – volume: 21
  start-page: 95
  year: 2020
  article-title: Efficacy and safety of erenumab in women with a history of menstrual migraine
  publication-title: J Headache Pain
– volume: 34
  start-page: 280
  year: 2014
  end-page: 288
  article-title: Prevalence of menstrual migraine: a population‐based study
  publication-title: Cephalalgia
– volume: 16
  start-page: 24
  year: 2015
  article-title: Burden of migraine related to menses: results from the AMPP study
  publication-title: J Headache Pain
– volume: 11
  start-page: 1683
  year: 2020
  article-title: Cerebrospinal fluid p‐tau217 performs better than p‐tau181 as a biomarker of Alzheimer's disease
  publication-title: Nat Commun
– volume: 38
  start-page: 1442
  year: 2018
  end-page: 1454
  article-title: Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE‐2 phase 3 randomized controlled clinical trial
  publication-title: Cephalalgia
– volume: 38
  start-page: 1
  year: 2018
  end-page: 211
  article-title: The International Classification of Headache Disorders, 3rd edition
  publication-title: Cephalalgia
– volume: 33
  start-page: 629
  year: 2013
  end-page: 808
  article-title: The International Classification of Headache Disorders, 3rd edition (beta version)
  publication-title: Cephalalgia
– volume: 78
  start-page: 1337
  year: 2012
  end-page: 1345
  article-title: Evidence‐based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society
  publication-title: Neurology
– volume: 2
  start-page: 327
  year: 2009
  end-page: 336
  article-title: Review: menstrual migraine: therapeutic approaches
  publication-title: Ther Adv Neurol Disord
– volume: 20
  start-page: 304
  year: 2021
  end-page: 315
  article-title: Menstrual migraine: a distinct disorder needing greater recognition
  publication-title: Lancet Neurol
– volume: 97
  start-page: e1753
  year: 2021
  end-page: e1756
  article-title: Differences between perimenstrual migraine attacks and migraine attacks at other times of the cycle
  publication-title: Neurology
– volume: 57
  start-page: 194
  year: 2017
  end-page: 208
  article-title: Menstrual migraine and treatment options: review
  publication-title: Headache
– volume: 24
  start-page: 707
  year: 2004
  end-page: 716
  article-title: Characteristics of menstrual and nonmenstrual attacks in women with menstrually related migraine referred to headache centres
  publication-title: Cephalalgia
– volume: 16
  start-page: 1231
  year: 2007
  end-page: 1237
  article-title: Validation of the migraine‐specific quality of life questionnaire version 2.1 (MSQ v. 2.1) for patients undergoing prophylactic migraine treatment
  publication-title: Qual Life Res
– volume: 42
  start-page: 1184
  year: 2022
  end-page: 1193
  article-title: Validation of diagnostic ICHD‐3 criteria for menstrual migraine
  publication-title: Cephalalgia
– volume: 142
  start-page: 24
  year: 2020
  end-page: 30
  article-title: Menstrual and perimenopausal migraine: a narrative review
  publication-title: Maturitas
– volume: 14
  start-page: 338
  year: 2018
  end-page: 350
  article-title: CGRP as the target of new migraine therapies—successful translation from bench to clinic
  publication-title: Nat Rev Neurol
– volume: 139
  start-page: 1226
  year: 2016
  end-page: 1236
  article-title: Cerebrospinal fluid analysis detects cerebral amyloid‐β accumulation earlier than positron emission tomography
  publication-title: Brain
– volume: 75
  start-page: 1080
  year: 2018
  end-page: 1088
  article-title: Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE‐1 randomized clinical trial
  publication-title: JAMA Neurol
– volume: 97
  start-page: e1661
  year: 2021
  end-page: e1671
  article-title: Comparing perimenstrual and nonperimenstrual migraine attacks using an E‐diary
  publication-title: Neurology
– volume: 17
  start-page: 621
  year: 2021
  end-page: 633
  article-title: Hormonal influences in migraine‐interactions of oestrogen, oxytocin and CGRP
  publication-title: Nat Rev Neurol
– volume: 100
  start-page: e1825
  year: 2023
  end-page: e1835
  article-title: Sex hormones and calcitonin gene–related peptide in women with migraine: a cross‐sectional, matched cohort study
  publication-title: Neurology
– ident: e_1_2_11_22_1
  doi: 10.1212/WNL.0b013e3182535d20
– ident: e_1_2_11_7_1
  doi: 10.1177/0333102413507637
– ident: e_1_2_11_17_1
  doi: 10.1001/jamaneurol.2018.1212
– ident: e_1_2_11_9_1
  doi: 10.1111/head.12978
– ident: e_1_2_11_13_1
  doi: 10.1212/WNL.0000000000012723
– ident: e_1_2_11_3_1
  doi: 10.1186/s10194-020-01167-6
– ident: e_1_2_11_8_1
  doi: 10.1177/0333102417738202
– ident: e_1_2_11_19_1
  doi: 10.1038/s41467-020-15436-0
– ident: e_1_2_11_18_1
  doi: 10.1093/brain/aww015
– ident: e_1_2_11_21_1
  doi: 10.1007/s11136-007-9217-1
– ident: e_1_2_11_12_1
  doi: 10.1177/03331024221099031
– ident: e_1_2_11_5_1
  doi: 10.1212/WNL.0000000000012741
– ident: e_1_2_11_10_1
  doi: 10.1111/j.1468-2982.2004.00741.x
– ident: e_1_2_11_16_1
  doi: 10.1177/0333102418779543
– ident: e_1_2_11_2_1
  doi: 10.1177/1756285609335537
– ident: e_1_2_11_4_1
  doi: 10.1016/j.maturitas.2020.07.005
– ident: e_1_2_11_11_1
  doi: 10.1186/s10194-015-0503-y
– ident: e_1_2_11_6_1
  doi: 10.1016/S1474-4422(20)30482-8
– ident: e_1_2_11_20_1
  doi: 10.1177/0333102413485658
– ident: e_1_2_11_14_1
  doi: 10.1038/s41582-018-0003-1
– ident: e_1_2_11_23_1
  doi: 10.1212/WNL.0000000000207114
– ident: e_1_2_11_15_1
  doi: 10.1038/s41582-021-00544-2
SSID ssj0004696
Score 2.4192843
Snippet Background We evaluated galcanezumab for migraine prevention in patients who met International Classification of Headache Disorders, 3rd edition criteria for...
We evaluated galcanezumab for migraine prevention in patients who met International Classification of Headache Disorders, 3rd edition criteria for menstrually...
BackgroundWe evaluated galcanezumab for migraine prevention in patients who met International Classification of Headache Disorders, 3rd edition criteria for...
SourceID proquest
pubmed
crossref
wiley
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 179
SubjectTerms Antibodies, Monoclonal, Humanized
calcitonin gene–related peptide antibody
Clinical trials
Criteria
Diaries
Double-Blind Method
Female
galcanezumab
Headache
Headaches
Humans
menstrual migraine
menstrually related migraine
Migraine
Migraine Disorders - drug therapy
Migraine Disorders - prevention & control
migraine prevention
Monoclonal antibodies
Patients
Placebos
Prevention
Prospective Studies
Quality of Life
Response rates
Standard error
Treatment Outcome
Title Effect of galcanezumab in women with episodic migraine meeting criteria for menstrually related migraine: A post hoc analysis of EVOLVE‐1 and EVOLVE‐2
URI https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fhead.14652
https://www.ncbi.nlm.nih.gov/pubmed/38017629
https://www.proquest.com/docview/2927059180
https://www.proquest.com/docview/2895261445
Volume 64
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB6VHioulJZXSlsZwYVKqfJwGhtxWcFWK0ShqmjVC4psx6ar7m5W2t1De-pP4MzP45cw4zzaUoQEtyS24ziesb-xPd8AvDKxzEuU3hDhMQ-5zVWo8kyFwlFYnEi71G8XHHzaGxzzD6fZ6RK8bX1han6IbsGNNMOP16TgSs9uKDnFsCc9z2gApsNahIiOkhtOkT44Vz0M51w03KR0jOe66O3Z6A7EvI1Y_ZSzvwpf24-tT5qc7y7metdc_sbj-L-teQgPGizKerXwrMGSnazDykGz2_4IftTUxqxyDOcR7AN7uRgrzYYT5okbGC3iMjsdzioswsbDbxRvwrKx9X7UDAckYoJWDIExPvRctWo0umDegcaWXYk3rMem1WzOzirDVEOTQtX2Tz5_POn_vPoe4-Py-jZ5DMf7_S_vBmETyyE0KULEUGcuEUoqRDy5cBnabSJ13HEjdaSkNhpxqeCYotF-VJInuswMmjua-PsQ5aRPYHlSTewzYOR5Ejk0hHRc8qjkIibGHomvKo2Rbi-A122fFqYhOqd4G6OiNXjoZxf-Zwfwsss7rek9_phrsxWNolHxWZHIJEdsGosogBddMion7bhgj1QLzCMkNZXzLICntUh11aSIDXAmkgHseMH4S_3FoN977682_iXzc7ifIASrz5hvwjJ2st1CCDXX23Av4YfbXmF-Ad_hF4k
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NbtQwELZQKxUuLeWnDS0wCC4gpcqP09i9rehWC-wWCbVVb5Ht2LBid7PS7h7oiUfomcfjSTrjZNMWEBLcktiOZXvG_sb2fMPYKxPLvETpDREe85DbXIUqz1QoHIXFibRL_XHB4Hi_d8rfn2fnzd0c8oWp-SHaDTfSDD9fk4LThvQNLacg9qToGc7AqxTSm6jzDz8lN9wifXiueiLOuWjYSekiz3XZ2-vRbyDzNmb1i87RRh1Zdea5Cumuyde9xVzvmYtfmBz_uz332XoDR6FTy88mu2MnD9jaoDlwf8h-1OzGUDnApQSHwV4sxkrDcAKeuwFoHxfsdDirsAiMh58p5ISFsfWu1IBzEpFBK0BsjB89Xa0ajb6B96GxZVviADowrWZz-FIZUA1TClXbPfvYP-v-_H4Z4-fy-jV5xE6Puidve2ETziE0KaLEUGcuEUoqBD25cBmabiJ13HEjdaSkNhqhqeCYotGEVJInuswMWjyaKPwQ6KSP2cqkmthtBuR8Ejm0hXRc8qjkIibSHom_Ko2Rbj9gr5eDWpiG65xCboyKpc1DnV34zg7YyzbvtGb4-GOu3aVsFI2Wz4pEJjnC01hEAXvRJqN-0qELjki1wDxCUlM5zwK2VctUW02K8AAXIxmwN14y_lJ_0et2Dv3Tk3_J_Jzd7Z0M-kX_3fGHHXYvQURWXznfZSs44PYpIqq5fub15gqvqBrO
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1LT9wwEB4hkFAvFZQ-ArRM1V5aKVIeDolRL6uyq6UFyqEgbpHt2O1Ku5uVFg5w4idw7s_rL-mMkw0gqkq95WHHiscz_sb2fAPw3sQyr2j0hgSPRShsrkKVZyosHKfFibRL_XbB0fHu8FR8Oc_Ol-DTIham4YfoFtxYM7y9ZgWfVe6eknMOe9bzjAzwCu_28YGuRJzci4r02bkaO5yLoiUn5XM8d3UfTkePMOZDyOrnnMEaPG3BIvYa6a7Dkp0-g9Wjdjt8A3413MNYOyRDT51kry8nSuNoip5ZAXmVFe1sNK-pCk5GPzghhMWJ9YHOSBaDqZoVEnKlh55MVo3HV-gjXGzV1djDHs7q-QX-rA2qlseEm-2ffTs86_--uY3pcXV3mzyH00H_--dh2CZbCE1KGC7UmUsKJRVBkrxwGTlWReqEE0bqSEltNAFH6mOXaXLwlBSJrjJD_ohmgj2CIekLWJ7WU_sKkENDIkeeio4rEVWiiJlSR9KnKmOk2w3gw6LPS9MykXNCjHG58EhYPqWXTwDvurKzhn_jr6W2F6IrWx2cl4lMcgKPcREF8LZ7TdrDWyIkkfqSyhSSf1WILICXjci7ZlKavGmqkAF89GPgH-2Xw35v319t_k_hHVg92R-UhwfHX7fgSUJwqTkPvg3LJG_7muDOhX7jR_UfRpv45w
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effect+of+galcanezumab+in+women+with+episodic+migraine+meeting+criteria+for+menstrually+related+migraine%3A+A+post+hoc+analysis+of+EVOLVE-1+and+EVOLVE-2&rft.jtitle=Headache&rft.au=MacGregor%2C+E+Anne&rft.au=Okonkwo%2C+Rose&rft.au=Detke%2C+Holland+C&rft.au=Polavieja%2C+Pepa&rft.date=2024-02-01&rft.issn=1526-4610&rft.eissn=1526-4610&rft.volume=64&rft.issue=2&rft.spage=179&rft_id=info:doi/10.1111%2Fhead.14652&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0017-8748&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0017-8748&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0017-8748&client=summon